
Oncology NEWS International
- Oncology NEWS International Vol 16 No 6
- Volume 16
- Issue 6
FDA Approves Torisel for Renal Cell Carcinoma
FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa
ROCKVILLE, MarylandFDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa. Median overall survival was 10.9 months for Torisel patients vs 7.3 months for interferon patients. Progression-free survival increased from 3.1 months with interferon to 5.5 months with Torisel. The combination of Torisel and interferon did not result in a significant increase in overall survival, compared with interferon alone. Look for a complete report on the approval in the July issue of ONI.
Articles in this issue
almost 19 years ago
ACS Launches Major Epidemiology Studyalmost 19 years ago
Pt Selection Key to Radioembolization of Liver Ca'salmost 19 years ago
Million Dollar Gotham Prize Announcedalmost 19 years ago
Diagnostic Dilemma: GI Diseasealmost 19 years ago
Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Ptsalmost 19 years ago
Junovan Fails to Win ODAC Nod for Osteosarcoma Treatmentalmost 19 years ago
Surveillance Colonoscopy Guidelines Not Being Followedalmost 19 years ago
Removing Stage IV Primary May Cut Mortalityalmost 19 years ago
Nuclear Export Inhibitors Testing Moving Forwardalmost 19 years ago
ODAC: orBec Yields No 'Substantial Efficacy' in GI GVHDNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































